AdAlta Limited

@AdAlta1AD

Targeting untreated diseases using the i-body: a unique drug discovery platform. ASX: 1AD.

Melbourne, Australia
Vrijeme pridruživanja: prosinac 2014.

Tweetovi

Blokirali ste korisnika/cu @AdAlta1AD

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AdAlta1AD

  1. 12. sij

    More evidence of big pharma interest in with Boehringer Ingelheim and Enleofen announcing a $US1bn + deal for fibro-inflammatory diseases. Our i-body based therapeutic, AD-214 is due to enter the clinic in 2020. $1AD

    Poništi
  2. 12. pro 2019.

    Thanks for the great coverage of our grant. The funding is to develop and clinically evaluate a radio-labelled version of AD-214 for imaging of the cell surface receptor CXCR4 in patients. More here: $1AD

    Poništi
  3. 11. pro 2019.

    Delighted to announce has been awarded A$1m in funding from Medical Research Future Fund’s program to develop an imaging agent for our lead therapeutic, AD-214. More: $1AD

    Poništi
  4. 17. stu 2019.

    More evidence of big pharma interest in Idiopathic Pulmonary with Roche's ~USD 1.39b acquisition of fibrosis-focused Promedior announced Friday. Our i-body based therapeutic, AD-214 is due to enter the clinic in 2020. $1AD

    Poništi
  5. 29. lis 2019.

    Chief Scientific Officer Mick Foley chairing AusBiotech Panel Discussion showing the strength of Australian biotech, "Anti-fibrotic drugs: A hot area for big pharma" with

    Poništi
  6. 28. lis 2019.

    As well as the good results from our non-human primate study, we’re pleased to announce that the GMP manufacturing of AD-214 for our phase 1 human study is now complete. $1AD Read the announcement here:

    Poništi
  7. 28. lis 2019.

    Pleased to announce we’ve completed our non-human primate study necessary to take our lead candidate, AD-214, into human clinical trials. The study showed AD-214 was safe and well-tolerated with no mortalities or adverse events. Read the announcement here:

    Poništi
  8. proslijedio/la je Tweet
    21. lis 2019.

    New CEO of , Dr Tim Oldham speaks about the company’s business development strategy of developing in-house assets to key inflection points and working in partnership with big Pharma / biotech to develop drugs of commercial interest to them. $1AD

    Poništi
  9. proslijedio/la je Tweet
    21. lis 2019.

    Chairman of , Paul MacLeman introduces the company and new CEO/MD, Dr Tim Oldham to investors at the 10th Annual Australian Microcap Conference. See the presentation here $1AD

    Poništi
  10. 14. lis 2019.
    Poništi
  11. 8. lis 2019.

    Dr Tim Oldham appointed as 's new CEO and MD. Dr Oldham has extensive expertise in portfolio building, biologic development and pipeline commercialisation. He starts with us Monday 14 Oct. Read more: $1AD

    Poništi
  12. proslijedio/la je Tweet
    8. lis 2019.

    Looking forward to seeing and presenting at this year’s microcap conference! $1AD

    Poništi
  13. 15. ruj 2019.

    Watch our Executive Chairman, Paul MacLeman talk with Finance News Network about our deal with to develop i-bodies for diagnostic imaging. Read the full announcement here: $1AD

    Poništi
  14. 15. ruj 2019.

    We are delighted to sign an agreement for our platform with global medical technology firm, GE Healthcare. The licensing deal will see us develop i-bodies for diagnostic imaging. Read full announcement here: $1AD

    Poništi
  15. 8. kol 2019.

    Excited to see interest growing in the target space with the partnership between and - great news for everyone involved in this sector

    Poništi
  16. 2. kol 2019.

    Fun Fact 3 : we will be in the clinic with our first i-body AD-214 for the treatment of IPF.

    Poništi
  17. proslijedio/la je Tweet
    1. kol 2019.

    This is a wobbegong shark. Fun fact 1: wobbegong sharks do not have to keep on moving in order for them to breathe. Fun fact 2: Their antibodies inspired i-bodies that @AdAltaCEO now produces.

    Prikaži ovu nit
    Poništi
  18. 18. srp 2019.

    Excited to see another early stage deal today. Boehringer has licensed Bridge Biotherapeutics’ IPF med for: EU45m upfront and EU1.1B in milestone payments. AdAlta enters the clinic in January with its candidate, .

    Poništi
  19. 24. lip 2019.

    “Scarred for life” case study profiles $1AD lead drug AD-214 for IPF -

    Poništi
  20. 18. lip 2019.

    AdAlta's i-body AD-214 featured in "Nanobody approval gives domain antibodies a boost"

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·